Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 16, 2014
- Accepted in final form October 13, 2014
- First Published December 11, 2014.
Author Disclosures
- Belén de la Hera, MS,
- Elena Urcelay, PhD,
- David Brassat, MD,
- Andrew Chan, MD,
- Angela Vidal-Jordana, MD,
- Anke Salmen, MD,
- Luisa Maria Villar, MD,
- José Carlos Álvarez-Cermeño, MD,
- Guillermo Izquierdo, MD,
- Oscar Fernández, MD,
- Begoña Oliver, PhD,
- Albert Saiz, MD,
- Jose Ramón Ara, MD,
- Ana G. Vigo, PhD,
- Rafael Arroyo, MD,
- Virginia Meca, MD,
- Sunny Malhotra, PhD,
- Nicolás Fissolo, PhD,
- Alejandro Horga, MD,
- Xavier Montalban, MD and
- Manuel Comabella, MD
- Belén de la Hera, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elena Urcelay, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Brassat, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew Chan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angela Vidal-Jordana, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anke Salmen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Maria Villar, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José Carlos Álvarez-Cermeño, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Guillermo Izquierdo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Oscar Fernández, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Begoña Oliver, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jose Ramón Ara, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana G. Vigo, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rafael Arroyo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Virginia Meca, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sunny Malhotra, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolás Fissolo, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alejandro Horga, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Montalban, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Manuel Comabella, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Immunology (B.d.l.H., E.U., A.G.V.) and Department of Neurology, Multiple Sclerosis Unit (R.A.), Hospital Clínico San Carlos (IdISSC), Madrid, Spain; Pole des neurosciences et INSERM U1043 (D.B.), Université de Toulouse III, Hopital Purpan, Toulouse, France; Department of Neurology (A.C., A. Salmen), St. Josef-Hospital, Ruhr University, Bochum, Germany; Servei de Neurologia-Neuroimmunologia (A.V.-J., S.M., N.F., A.H., X.M., M.C.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Departments of Neurology and Immunology (L.M.V., J.C.A.-C.), Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain; Hospital Universitario Virgen Macarena (G.I.), Seville, Spain; Unidad de Gestión Clínica de Neurociencias (O.F., B.O.), Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Regional de Málaga, Universidad de Málaga, Spain; Service of Neurology (A. Saiz), Hospital Clínic, Universitat de Barcelona and Institut d´Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Biochemistry, Molecular and Cellular Biology (J.R.A.), Science Faculty, University of Zaragoza, Spain; and Fundación de Investigación Biomédica (V.M.), Hospital Universitario de la Princesa, Madrid, Spain.
- Correspondence to Dr. Comabella: manuel.comabella{at}vhir.org
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
-
Editorial
The genetics of natalizumab hypersensitivityOne learns to itch where one can scratchOlaf Stüve, Bernhard Hemmer et al.Neurology - Neuroimmunology Neuroinflammation, December 11, 2014 -
Article
Genetic determinants of the humoral immune response in MSChristiane Gasperi, Till F.M. Andlauer, Ana Keating et al.Neurology: Neuroimmunology & Neuroinflammation, July 16, 2020 -
Articles
Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathyN. A. Sutedja, H. G. Otten, E. A. Cats et al.Neurology, March 08, 2010 -
Article
Genetic risk variants in African Americans with multiple sclerosisNoriko Isobe, Pierre-Antoine Gourraud, Hanne F. Harbo et al.Neurology, June 14, 2013